|
Prognostic Marker
|
Log-rank p-value
|
Total number
|
Events
|
|---|
|
Non-Stratified
|
|
IGF1R
|
0.018*
|
233
|
19
|
|
SphK1
|
0.427
|
233
|
19
|
|
IGF1R/SphK1
|
0.028*
|
232
|
19
|
|
pIGF1R
|
0.303
|
232
|
19
|
|
pIGF1R/SphK1
|
0.118
|
232
|
19
|
|
ER-positive
|
|
IGF1R
|
0.048*
|
165
|
11
|
|
SphK1
|
0.250
|
165
|
11
|
|
IGF1R/SphK1
|
0.051
|
165
|
11
|
|
ER-negative
|
|
IGF1R
|
0.445
|
68
|
8
|
|
SphK1
|
0.675
|
68
|
8
|
|
IGF1R/SphK1
|
0.582
|
68
|
8
|
|
Anti-Endocrine Therapy (AET)
|
|
AET-positive vs. AET-negative
|
0.006*
|
190
|
17
|
|
AET-positive
|
|
IGF1R
|
0.028*
|
190
|
17
|
|
SphK1
|
0.101
|
190
|
17
|
|
IGF1R/SphK1
|
0.034*
|
190
|
17
|
|
HER2-negative
|
|
IGF1R
|
0.074
|
143
|
4
|
|
SphK1
|
0.052
|
143
|
4
|
|
pIGF1R
|
0.273
|
142
|
4
|
|
HER2-positive
|
|
IGF1R
|
0.195
|
86
|
14
|
|
SphK1
|
0.062
|
86
|
14
|
|
pIGF1R
|
0.858
|
86
|
14
|
|
PR-negative
|
|
IGF1R
|
0.290
|
81
|
10
|
|
SphK1
|
0.296
|
81
|
10
|
|
pIGF1R
|
0.410
|
81
|
10
|
|
PR-positive
|
|
IGF1R
|
0.101
|
147
|
8
|
|
SphK1
|
0.293
|
147
|
8
|
|
pIGF1R
|
0.588
|
146
|
8
|
- High vs. low prognostic marker expression *p-value significant; ≤0.05
